Navigation Links
BioWa Announces License of POTELLIGENT(R) Technology to sanofi-aventis

PRINCETON, N.J., April 8 /PRNewswire/ -- BioWa, Inc. announced today that it has entered into a license agreement with sanofi-aventis (EURONEXT: SAN and NYSE: SNY), providing the global healthcare company with access to BioWa's POTELLIGENT(R) Technology platform for the research, development and commercialization of their antibody therapies with enhanced antibody-dependent cellular cytotoxicity (ADCC).

"We are extremely pleased about our partnership with sanofi-aventis, a global healthcare company with a strong worldwide presence," commented Dr. Masamichi Koike, BioWa's President and CEO. "Sanofi-aventis' world-class R&D organization and global market presence will enable us to promote and extend the benefit of the technology to patients all over the world more efficiently."

"By working with BioWa's POTELLIGENT(R) Technology, we will further improve the mechanism of action of our therapeutic antibodies and make them more potent and more effective against targeted diseases," added Jean-Marc Herbert, Senior Vice President Discovery Research, sanofi-aventis.

Under the terms of the license agreement, BioWa grants sanofi-aventis non-exclusive rights to research, develop and commercialize therapeutic antibodies generated through POTELLIGENT(R) Technology for an undisclosed number of targets. In return, BioWa will receive upfront payments, and may receive development milestone payments and royalties on products. Other details of the agreement are not disclosed.

About POTELLIGENT(R) Technology

POTELLIGENT(R) Technology improves potency and efficacy of antibody therapeutics, by enhancing ADCC, one of the major mechanisms of action for antibody therapeutics. POTELLIGENT(R) Technology involves the reduction of the amount of fucose in the carbohydrate structure of an antibody using a proprietary fucosyltransferase-knockout CHO cell line as a production cell. Research shows that POTELLIGENT(R) Technology dramatically enhances ADCC activity of an antibody in vitro, and significantly increases potency and efficacy of the antibody in vivo. A number of POTELLIGENT(R) antibodies are being investigated in human clinical trials.

About BioWa, Inc.

BioWa is a wholly owned subsidiary of Kyowa Hakko Kirin Co., Ltd., Japan's leading pharmaceutical and largest biotech company, and is the exclusive worldwide licensor of AccretaMab(TM) platform. AccretaMab(TM) platform consists of POTELLIGENT(R) and COMPLEGENT(TM) Technologies, creating a superior antibody molecule with enhanced ADCC and CDC activities. BioWa is offering POTELLIGENT(R) and COMPLEGENT(TM) Technologies to partners under a license to maximize the value of these technologies. Together with Kyowa Hakko Kirin, BioWa is committed to promote ADCC/CDC enhanced monoclonal antibody-based therapeutics to fight cancer and other life-threatening and debilitating diseases. For more information about BioWa, visit its web site at

POTELLIGENT(R), COMPLEGENT(TM), and AccretaMab(TM) are the trademarks of Kyowa Hakko Kirin Co., Ltd. All rights are reserved.

About sanofi-aventis

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

SOURCE BioWa, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. BioWa Licenses POTELLIGENT(R) Technology to GlaxoSmithKline for Use in Antibody Development and Commercialization
2. BioWa Announces License of Biowas Potelligent(R) Technology to KaloBios Pharmaceuticals
3. BioWa and Medarex Announce License of BioWas COMPLEGENT(TM) Technology
4. Increased Light Leads to Early Detection: Caliper Life Sciences Introduces Bioware(R) Ultra Cancer Cell Lines
5. BioWa Announces Expansion of License Agreement with Genentech for BioWas POTELLIGENT(R) Technology
6. BioWa Announces Licensing of BioWas POTELLIGENT(R) Technology by GlaxoSmithkline for Use in Antibody Research and Development
7. EnWave Announces Collaboration and Initial Testing Results with Danisco AS
8. Microbix Announces A New Technology Platform For The SST Project
9. Oncolytics Biotech(R) Inc. Announces Positive Results of U.K. Phase II REOLYSIN(R) and Radiation Combination Clinical Trial
10. Caliper Life Sciences Announces Date and Location of its 2009 Annual Meeting of Stockholders
11. Immunotech Laboratories Announces South American Strategy
Post Your Comments:
(Date:6/23/2016)... June 23, 2016 A person commits a crime, ... scene to track the criminal down. An outbreak ... and Drug Administration (FDA) uses DNA evidence to track down ... Sound far-fetched? It,s not. The FDA has increasingly used ... investigations of foodborne illnesses. Put as simply as possible, whole ...
(Date:6/23/2016)... June 23, 2016  The Prostate Cancer Foundation (PCF) is pleased ... and faster cures for prostate cancer. Members of the Class of 2016 were ... Read More About the Class of 2016 PCF Young ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, ... of the Supplyframe Design Lab . Located in Pasadena, Calif., the Design ... of how hardware projects are designed, built and brought to market. , The ...
(Date:6/23/2016)... Ky. , June 23, 2016 ... two Phase 1 clinical trials of its complement ... placebo-controlled, single and multiple ascending dose studies designed ... pharmacodynamics (PD) of subcutaneous injection in healthy adult ... subcutaneously (SC) either as a single dose (ranging ...
Breaking Biology Technology:
(Date:5/12/2016)... 2016 , a brand of ... results from the Q1 wave of its quarterly wearables ... consumers, receptivity to a program where they would receive ... insurance company. "We were surprised to see ... Michael LaColla , CEO of Troubadour Research, "primarily because ...
(Date:4/28/2016)... 2016 First quarter 2016:   ... with the first quarter of 2015 The gross margin ... (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... unchanged, SEK 7,000-8,500 M. The operating margin for 2016 ...
(Date:4/15/2016)... , April 15, 2016  A new partnership ... more accurate underwriting decisions in a fraction of ... competitively priced and high-value life insurance policies to ... With Force Diagnostics, rapid testing (A1C, ... data readings (blood pressure, weight, pulse, BMI, and ...
Breaking Biology News(10 mins):